WO2001025282A1 - Mutants il13 - Google Patents

Mutants il13 Download PDF

Info

Publication number
WO2001025282A1
WO2001025282A1 PCT/US2000/027567 US0027567W WO0125282A1 WO 2001025282 A1 WO2001025282 A1 WO 2001025282A1 US 0027567 W US0027567 W US 0027567W WO 0125282 A1 WO0125282 A1 WO 0125282A1
Authority
WO
WIPO (PCT)
Prior art keywords
mutant
cell
receptor
composition
cells
Prior art date
Application number
PCT/US2000/027567
Other languages
English (en)
Inventor
Waldemar Debinski
Jeffrey P. Thompson
Original Assignee
The Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Penn State Research Foundation filed Critical The Penn State Research Foundation
Priority to EP00968773A priority Critical patent/EP1222212A4/fr
Priority to JP2001528448A priority patent/JP2003511019A/ja
Priority to CA002386248A priority patent/CA2386248A1/fr
Priority to AU78639/00A priority patent/AU7863900A/en
Publication of WO2001025282A1 publication Critical patent/WO2001025282A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne des molécules d'interleukine 13 humaine mutantes faisant preuve d'une spécificité différente pour le récepteur limité de l'IL13 (indépendant de l'IL14). Les molécules de l'hIL13 mutantes sont constituées de celles formées par substitution des restes d'acides aminés présents dans les zones sous forme d'alpha hélice d'hIL13 native avec d'autres restes d'acides aminés. Certains mutants conservent la capacité de se lier et d'assurer la signalisation à travers les récepteurs d'IL13 au détriment d'autres mutants.
PCT/US2000/027567 1999-10-06 2000-10-05 Mutants il13 WO2001025282A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00968773A EP1222212A4 (fr) 1999-10-06 2000-10-05 Mutants il13
JP2001528448A JP2003511019A (ja) 1999-10-06 2000-10-05 Ｉｌ１３変異体
CA002386248A CA2386248A1 (fr) 1999-10-06 2000-10-05 Mutants il13
AU78639/00A AU7863900A (en) 1999-10-06 2000-10-05 Il13 mutants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15793499P 1999-10-06 1999-10-06
US60/157,934 1999-10-06

Publications (1)

Publication Number Publication Date
WO2001025282A1 true WO2001025282A1 (fr) 2001-04-12

Family

ID=22565965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027567 WO2001025282A1 (fr) 1999-10-06 2000-10-05 Mutants il13

Country Status (5)

Country Link
EP (1) EP1222212A4 (fr)
JP (1) JP2003511019A (fr)
AU (1) AU7863900A (fr)
CA (1) CA2386248A1 (fr)
WO (1) WO2001025282A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034645A2 (fr) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
EP1140167A1 (fr) * 1999-01-07 2001-10-10 The Penn State Research Foundation Procede de diagnostic, d'imagerie et de traitement des tumeurs au moyen d'un recepteur restrictif pour l'interleukine 13
WO2003039600A1 (fr) * 2001-11-09 2003-05-15 Neopharm, Inc. Traitement selectif des tumeurs exprimant l'interleukine 13
EP1315742A1 (fr) * 2000-08-30 2003-06-04 The Penn State Research Foundation Mutants de substitution d'acides amines de l'interleukine 13
WO2006113614A2 (fr) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health Methodes de traitement et de prevention de la maladie intestinale inflammatoire agissant sur il-3 et sur les cellules nkt
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7615213B2 (en) 2004-06-09 2009-11-10 Wyeth Antibodies against human interleukin-13 and pharmaceutical compositions thereof
CN102993302A (zh) * 2003-12-23 2013-03-27 遗传技术研究公司 新的抗il-13抗体及其应用
EP2850093A4 (fr) * 2012-01-27 2016-03-02 Univ Leland Stanford Junior Polypeptides d'il-13 thérapeutiques
US11352402B2 (en) 2013-09-24 2022-06-07 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EP1206288B1 (fr) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Effecteurs radiatifs cibles exempts de fibres

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEBINSKI W. ET AL.: "Novel anti-brain tumor cytotoxins specific for cancer cells", NATURE BIOTECHNOLOGY, vol. 16, May 1998 (1998-05-01), pages 449 - 453, XP002938403 *
DEBINSKI W. ET AL.: "Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells", J. BIOL. CHEM., vol. 271, no. 37, September 1996 (1996-09-01), pages 22428 - 22433, XP002938404 *
PASTAN ET AL.: "Recombinant toxins as novel therapeutic agents", ANN. REV. BIOCHEM., vol. 61, 1992, pages 331 - 354, XP002938402 *
See also references of EP1222212A4 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
EP1140167A1 (fr) * 1999-01-07 2001-10-10 The Penn State Research Foundation Procede de diagnostic, d'imagerie et de traitement des tumeurs au moyen d'un recepteur restrictif pour l'interleukine 13
EP1140167A4 (fr) * 1999-01-07 2005-05-25 Penn State Res Found Procede de diagnostic, d'imagerie et de traitement des tumeurs au moyen d'un recepteur restrictif pour l'interleukine 13
WO2001034645A3 (fr) * 1999-11-11 2002-03-07 Us Health Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
WO2001034645A2 (fr) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
EP1315742A1 (fr) * 2000-08-30 2003-06-04 The Penn State Research Foundation Mutants de substitution d'acides amines de l'interleukine 13
JP2004507264A (ja) * 2000-08-30 2004-03-11 ザ　ペン　ステート　リサーチ　ファウンデーション インターロイキン１３のアミノ酸置換変異体
EP1315742A4 (fr) * 2000-08-30 2004-08-11 Penn State Res Found Mutants de substitution d'acides amines de l'interleukine 13
JP4863150B2 (ja) * 2000-08-30 2012-01-25 ザ・ペン・ステート・リサーチ・ファンデーション インターロイキン１３のアミノ酸置換変異体
WO2003039600A1 (fr) * 2001-11-09 2003-05-15 Neopharm, Inc. Traitement selectif des tumeurs exprimant l'interleukine 13
JP2005508375A (ja) * 2001-11-09 2005-03-31 ネオファーム、インコーポレイティッド Ｉｌ−１３を発現する腫瘍の選択的治療
CN102993302A (zh) * 2003-12-23 2013-03-27 遗传技术研究公司 新的抗il-13抗体及其应用
US7615213B2 (en) 2004-06-09 2009-11-10 Wyeth Antibodies against human interleukin-13 and pharmaceutical compositions thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
WO2006113614A2 (fr) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health Methodes de traitement et de prevention de la maladie intestinale inflammatoire agissant sur il-3 et sur les cellules nkt
EP2850093A4 (fr) * 2012-01-27 2016-03-02 Univ Leland Stanford Junior Polypeptides d'il-13 thérapeutiques
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
US9732133B2 (en) 2012-01-27 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic IL-13 polypeptides
US10227389B2 (en) 2012-01-27 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic IL-13 polypeptides
US11084858B2 (en) 2012-01-27 2021-08-10 The Board of Trustees of the Leland Stanford Junior University Stanford, CA Therapeutic IL-13 polypeptides
US11352402B2 (en) 2013-09-24 2022-06-07 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof

Also Published As

Publication number Publication date
EP1222212A4 (fr) 2005-05-04
AU7863900A (en) 2001-05-10
CA2386248A1 (fr) 2001-04-12
JP2003511019A (ja) 2003-03-25
EP1222212A1 (fr) 2002-07-17

Similar Documents

Publication Publication Date Title
US6576232B1 (en) IL13 mutants
JP4202417B2 (ja) Ｉｌ−１３受容体特異的キメラタンパク質およびその用途
US6428788B1 (en) Compositions and methods for specifically targeting tumors
US6296843B1 (en) Mutagenized IL 13-based chimeric molecules
JP6622814B2 (ja) イメージングのための新規ｐｄ−ｌ１結合ポリペプチド
US7750136B2 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
US6884603B2 (en) Nucleic acids encoding IL13 mutants
AU2001288405B2 (en) Amino acid substitution mutants of interleukin 13
EP1222212A1 (fr) Mutants il13
US6630576B2 (en) Amino acid substitution mutants of interleukin 13
CA2333923A1 (fr) Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15
US20030129132A1 (en) IL-13 receptor specific chimeric proteins & uses thereof
AU2001288405A1 (en) Amino acid substitution mutants of interleukin 13

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000968773

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2386248

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 528448

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 78639/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000968773

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642